Lungforskningsbolag kan andas ut efter fulltecknad nyemission

Medicinteknikbolaget Pexa har beslutat att upprätta kontrollbalansräkning – men genomför också en fullt garanterad företrädesemission för att återupprätta sitt aktiekapital.

Heidi Stensmyren is eager for new challenges in the biotech industry

Heidi Stensmyren has served as President of the Swedish Medical Association, held a managerial position at Karolinska University Hospital and is now Medical Dir...

The first drugs to slow down Alzheimer’s – but what does it mean for patients?

New treatments for early Alzheimer’s are bringing hope to thousands of patients and their families. The question is, who will get the treatment, how will the ri...

New report: Fewer PhDs in life sciences

A new report from Vinnova suggests that competency returns in the life science sector are declining.

Exploring Molecular Dynamics with Raster Image Correlation Spectroscopy

Understand how RICS can be used to measure diffusion coefficients.

Norwegian company wins bidding battle for Sensidose

The lengthy battle to acquire medical device company Sensidose is apparently over. Generic medicines company EQL Pharma is pulling out, selling its shares and l...

Anna Törner: ”Orphan Designation – the "petite robe noire" of drug development”

It is easy to cling to various regulatory incentives, like orphan designation, and other expedited pathways, without understanding what they truly mean or wheth...

Fast Optical Sectioning of Developing Organisms and Tissue Microstructures

ZEISS Lattice SIM 3 exploits the full potential of the SIM Apotome technology.

Novo Nordisk invests billions in expanding its production capacity

Danish pharmaceutical company Novo Nordisk is making a major investment to develop and expand its production facility in Hillerød, north of Copenhagen. DKK 15.9...

Automate E2E Image Analysis Pipelines

ZEISS arivis Pro - Your End-to-End Scientific Image Analysis Software.

Doge backar om nedläggning av viktigt FDA-labb

Trumpadministrationen drar efter kritik tillbaka beslutet att stänga ett av FDA:s viktigaste laboratorier för läkemedelskontroll.

Are you curious about volume imaging for very large samples?

Exciting ZEISS Webinar!

Quiet, fast, inexpensive: mass flow controller for life sciences

Whether in portable oxygen system devices or in bioreactors, the new proportional flow control valve VEMD from Festo provides extremely high control dynamics an...

High biological age is linked to a higher risk of dementia and stroke

It is a well-known fact that people age at different rates, and a recent study at the Karolinska Institute suggests that people with a biological age higher tha...

ZEISS O-INSPECT duo: The multifunctional measuring machine

ZEISS O-INSPECT duo combines advanced microscopy and metrology for impressive measurement accuracy.

Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future”

of Swedish medicine. He is now being awarded the Research!Sweden Award 2023.

Raised millions to develop a treatment for ´butterfly children´

Fragile as a butterfly’s wing – that’s how people living with Epidermolysis Bullosa are usually described. The Lund-based company Xinnate recently raised SEK 100 million in a new...

Introducing ZEISS arivis Pro 4.2

Your solution for advanced image analysis and visualization.

Eli Lilly to build a USD 2.5-billion plant in Germany

US-based Eli Lilly is planning a huge investment of USD 2.5 billion, equivalent to around SEK 26.5 billion, in a new production facility in Alzey, Germany.

"Unclear proposal from the EU Commission on how to solve the MDR challenges"

Even before the EU regulation on medical devices (MDR) came into force, medical technology companies and doctors were concerned that it would endanger the avail...

No longer afraid of the dentist.

Teaching robot with piezo technology

Bioscience – Groundbreaking Research & Diagnostics: Gothenburg (2026)

To build trust, one must be able to say “I don’t know” – whether human or AI

Will AI strengthen or break down trust? It depends on whether we can understand and accept its limitations, and our own, writes Sarah Lidé in a column.

Editorial: ”AI that both impresses and frightens”

”In the past, I've rarely been particularly impressed by something that was produced by AI. But this is something completely different”, Samuel Lagercrantz writ...